Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug‐Resistant HIV‐1 Infection | Zendy

Steven G. Deeks | Zendy; Rebecca Hoh | Zendy; Torsten B. Neilands | Zendy; Teri Liegler | Zendy; Francesca Aweeka | Zendy; Christos J. Petropoulos | Zendy; Robert M. Grant | Zendy; Jeffrey N. Martin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interruption of Treatment with Individual Therapeutic Drug Classes in Adults with Multidrug‐Resistant HIV‐1 Infection

Author(s) -

Steven G. Deeks,

Rebecca Hoh,

Torsten B. Neilands,

Teri Liegler,

Francesca Aweeka,

Christos J. Petropoulos,

Robert M. Grant,

Jeffrey N. Martin

Publication year - 2005

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/496892

Subject(s) - resistance mutation , drug resistance , multiple drug resistance , virology , protease inhibitor (pharmacology) , drug holiday , reverse transcriptase inhibitor , drug , medicine , viral load , virus , reverse transcriptase , lentivirus , sida , nucleoside , viral replication , viral disease , biology , immunology , human immunodeficiency virus (hiv) , pharmacology , rna , antiretroviral therapy , microbiology and biotechnology , gene , biochemistry

Many antiretroviral-treated human immunodeficiency virus (HIV)-infected patients experience sustained immunologic and virologic benefit despite the presence of multidrug-resistant HIV. We hypothesized that the use of simplified regimens could maintain treatment benefit while preventing viral evolution and reducing drug-related toxicity and costs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research